Do low vitamin B12 and folate with high MMA and homocysteine indicate impaired one-carbon metabolism?

In older adults, such as a 68-year-old male, the co-occurrence of low vitamin B12 and low folate alongside elevated methylmalonic acid (MMA) and homocysteine indicates a profound disruption of one-carbon metabolism. This metabolic block has severe, direct consequences on red blood cell production and neurological integrity.

Mechanistic pathways of metabolic block

• Enzymatic cofactor failure: Cytosolic remethylation of homocysteine to methionine relies on folate and vitamin B12. Deficiencies in these vitamins block this pathway, leading to hyperhomocysteinemia. Concurrently, mitochondrial methylmalonyl-CoA mutase requires B12 to produce succinyl-CoA; its failure causes MMA accumulation.
• Intracellular biomarkers: Elevated levels of both MMA and homocysteine serve as highly sensitive, functional indicators of intracellular vitamin depletion, reflecting pathway failure more accurately than static serum vitamin levels alone.

Pathophysiology of macrocytic anemia

• Impaired DNA synthesis: Impaired one-carbon metabolism depletes the 5,10-methylene tetrahydrofolate pool required by thymidylate synthase to convert dUMP to dTMP, halting DNA replication.
• Megaloblastic progression: In rapidly dividing erythroid precursors, defective DNA replication coupled with ongoing cytoplasmic growth causes nuclear-cytoplasmic asynchrony. This manifests clinically as megaloblastic macrocytic anemia, characterized by an elevated mean corpuscular volume (MCV > 100 fL, and frequently > 110 fL).

Neurocognitive impact and clinical efficacy

• Neurological decline: A reduced S-adenosylmethionine (SAM) to S-adenosylhomocysteine (SAH) ratio causes DNA hypomethylation, upregulating PSEN1 and BACE1 promoters to drive amyloid-beta and tau pathology. Concurrently, elevated homocysteine promotes direct neurovascular injury, excitotoxicity, and neurotransmitter depletion.
• Therapeutic limitations: Although correcting these metabolic deficiencies via B-vitamin supplementation successfully lowers homocysteine, clinical trials show inconsistent cognitive benefits, with improvements largely limited to individuals with baseline deficiencies or early mild cognitive impairment.

Bottom line

• Co-occurring low B12 and folate with elevated MMA and homocysteine confirm functional impairment of one-carbon metabolism, directly driving macrocytic anemia (MCV > 100 fL) via DNA synthesis failure and contributing to neurocognitive decline through epigenetic dysregulation and neurotoxicity.